Clinical Trials Logo
  1. Home
  2. Catheter Ablation
  3. NCT04780438

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

Catheter Ablation Clinical Trial

Official title:
Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

Clinical Trial Summary

Transcatheter left atrial antral ablation, aiming at complete electrical isolation of the pulmonary veins (PVI), has become mainstay in atrial fibrillation (AF) treatment. This approach has been proved superior to medical rhytmh control strategy in maintaining sinus rhythm. Moreover PVI has been associated with significant survival benefit in patients with heart failure and reduced left ventricular ejection fraction. Nevertheless, despite progress in the field of catheter ablation, recurrence rates remain high. Inhibitors of type 2 sodium- glucose co-transporter (SGLT2i) is a relatively recent addition to the array of anti-diabetic agents, becoming part of everyday clinical practice. However, although SGLT2i were first used solely as antidiabetics because of their glycosuric effect, further research demonstrated that these drugs may independently reduce cardiovascular events, especially in patients with heart failure, a benefit that was consistent among diabetic and non-diabetic patients. Moreover, pleiotropic effects have been observed, including a reno-protective action. These findings suggest that SGLT2i mechanisms of action extend beyond the obvious increase in urinary sodium and glucose excretion. Various studies propose that these drugs promote favourable metabolic changes in myocardial energetics, while they also inhibit inflamation and sympathetic activation, resulting in restriction of induced fibrosis and structural remodeling, which are key elements in atrial fibrillation generation and maintenance. These findings suggest that the use of SGLT2i could offer antiarrhythmic benefit by reducing and/or reversing structural and electrical remodeling, leading to the assumption that use of theese drugs could reduce recurrences after transcatheter AF ablation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04780438
Study type Interventional
Source G.Gennimatas General Hospital
Contact Spyridon Deftereos, Prof.
Email spdeftereos@gmail.com
Status Not yet recruiting
Phase Early Phase 1
Start date September 1, 2021
Completion date December 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03593486 - Low-Level EMF Stimulation for Paroxysmal Atrial Fibrillation N/A
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Active, not recruiting NCT06124690 - Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas N/A
Recruiting NCT05251545 - Randomized Trial: High Power Short Duration Versus Ablation Index N/A
Active, not recruiting NCT03695484 - Registry Evaluating AF Ablation Techniques
Recruiting NCT05777850 - High-Power Short-Duration Radiofrequency Ablation in Patients With Typical Atrial Flutter N/A
Not yet recruiting NCT05565183 - Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation. N/A
Recruiting NCT06160076 - Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2
Not yet recruiting NCT05575544 - Electroacupuncture Intervention in Catheter Ablation of Atrial Fibrillation N/A
Recruiting NCT04678258 - Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation N/A
Active, not recruiting NCT01630031 - Contact Force Sensing and Pulmonary Vein Isolation N/A
Completed NCT04896424 - Vagal Response and Cardiac Autonomic Modulation. Insides From Cryoballoon Ablation N/A
Completed NCT04906720 - Post-Ablation Pericarditis Reduction Study Phase 2
Not yet recruiting NCT05273645 - PrOgnosis Following Esophageal fisTula formaTion in Pts Undergoing cathetER Ablation for AF Study
Completed NCT03140631 - Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Phase 4
Active, not recruiting NCT03514693 - Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation N/A
Recruiting NCT03832959 - Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study. N/A
Not yet recruiting NCT05716581 - Prognostic Factors for Ablation of Atrial Fibrillation
Active, not recruiting NCT04405258 - Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial Phase 4
Completed NCT03340922 - MANual vs. automatIC Local Activation Time Annotation for Guiding Premature Ventricular Complex Ablation Phase 4